Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer

Carolyn Kim, Arta M Monjazeb, Mohan Suntharalingam, Kim R. Giesinger, A. William Blackstock

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chemoradiotherapy (CRT) is commonly employed in the management of esophageal carcinoma - either definitively or as part of a trimodality strategy with includes surgical resection. For patients treated with trimodality therapy, the most optimal sequence of chemoradiation (CRT) in relation to surgical resection is unclear. We reviewed the efficacy, advantages, and disadvantages of preoperative CRT versus postoperative CRT in esophageal cancer patients treated with trimodality therapy. Preoperative chemoradiation enables early treatment of distant metastases while simultaneously treating the primary disease, facilitates definition of radiotherapy target volumes, and may allow resection of advanced disease. It does, however, have considerable toxicity and may reduce the ability of some patients to tolerate resection. Postoperative CRT allows for early debulking, rapidly addresses dysphagia, and allows for CRT based on accurate pathologic staging, but delays systemic treatment. Randomized studies that compare preoperative with postoperative CRT in treating esophageal cancer are needed to identify conclusively the best standard of care. Based on the study information currently available, we conclude that treatment options should be tailored to the individual patient.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalClinical Advances in Hematology and Oncology
Volume7
Issue number5
StatePublished - 2009
Externally publishedYes

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Therapeutics
Standard of Care
Deglutition Disorders
Radiotherapy
Neoplasm Metastasis
Carcinoma

Keywords

  • Esophageal cancer
  • Radiotherapy
  • Trimodality therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer. / Kim, Carolyn; Monjazeb, Arta M; Suntharalingam, Mohan; Giesinger, Kim R.; Blackstock, A. William.

In: Clinical Advances in Hematology and Oncology, Vol. 7, No. 5, 2009, p. 327-334.

Research output: Contribution to journalArticle

Kim, Carolyn ; Monjazeb, Arta M ; Suntharalingam, Mohan ; Giesinger, Kim R. ; Blackstock, A. William. / Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer. In: Clinical Advances in Hematology and Oncology. 2009 ; Vol. 7, No. 5. pp. 327-334.
@article{d8e7fe98fdb94b6bacb88635a549fd07,
title = "Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer",
abstract = "Chemoradiotherapy (CRT) is commonly employed in the management of esophageal carcinoma - either definitively or as part of a trimodality strategy with includes surgical resection. For patients treated with trimodality therapy, the most optimal sequence of chemoradiation (CRT) in relation to surgical resection is unclear. We reviewed the efficacy, advantages, and disadvantages of preoperative CRT versus postoperative CRT in esophageal cancer patients treated with trimodality therapy. Preoperative chemoradiation enables early treatment of distant metastases while simultaneously treating the primary disease, facilitates definition of radiotherapy target volumes, and may allow resection of advanced disease. It does, however, have considerable toxicity and may reduce the ability of some patients to tolerate resection. Postoperative CRT allows for early debulking, rapidly addresses dysphagia, and allows for CRT based on accurate pathologic staging, but delays systemic treatment. Randomized studies that compare preoperative with postoperative CRT in treating esophageal cancer are needed to identify conclusively the best standard of care. Based on the study information currently available, we conclude that treatment options should be tailored to the individual patient.",
keywords = "Esophageal cancer, Radiotherapy, Trimodality therapy",
author = "Carolyn Kim and Monjazeb, {Arta M} and Mohan Suntharalingam and Giesinger, {Kim R.} and Blackstock, {A. William}",
year = "2009",
language = "English (US)",
volume = "7",
pages = "327--334",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "5",

}

TY - JOUR

T1 - Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer

AU - Kim, Carolyn

AU - Monjazeb, Arta M

AU - Suntharalingam, Mohan

AU - Giesinger, Kim R.

AU - Blackstock, A. William

PY - 2009

Y1 - 2009

N2 - Chemoradiotherapy (CRT) is commonly employed in the management of esophageal carcinoma - either definitively or as part of a trimodality strategy with includes surgical resection. For patients treated with trimodality therapy, the most optimal sequence of chemoradiation (CRT) in relation to surgical resection is unclear. We reviewed the efficacy, advantages, and disadvantages of preoperative CRT versus postoperative CRT in esophageal cancer patients treated with trimodality therapy. Preoperative chemoradiation enables early treatment of distant metastases while simultaneously treating the primary disease, facilitates definition of radiotherapy target volumes, and may allow resection of advanced disease. It does, however, have considerable toxicity and may reduce the ability of some patients to tolerate resection. Postoperative CRT allows for early debulking, rapidly addresses dysphagia, and allows for CRT based on accurate pathologic staging, but delays systemic treatment. Randomized studies that compare preoperative with postoperative CRT in treating esophageal cancer are needed to identify conclusively the best standard of care. Based on the study information currently available, we conclude that treatment options should be tailored to the individual patient.

AB - Chemoradiotherapy (CRT) is commonly employed in the management of esophageal carcinoma - either definitively or as part of a trimodality strategy with includes surgical resection. For patients treated with trimodality therapy, the most optimal sequence of chemoradiation (CRT) in relation to surgical resection is unclear. We reviewed the efficacy, advantages, and disadvantages of preoperative CRT versus postoperative CRT in esophageal cancer patients treated with trimodality therapy. Preoperative chemoradiation enables early treatment of distant metastases while simultaneously treating the primary disease, facilitates definition of radiotherapy target volumes, and may allow resection of advanced disease. It does, however, have considerable toxicity and may reduce the ability of some patients to tolerate resection. Postoperative CRT allows for early debulking, rapidly addresses dysphagia, and allows for CRT based on accurate pathologic staging, but delays systemic treatment. Randomized studies that compare preoperative with postoperative CRT in treating esophageal cancer are needed to identify conclusively the best standard of care. Based on the study information currently available, we conclude that treatment options should be tailored to the individual patient.

KW - Esophageal cancer

KW - Radiotherapy

KW - Trimodality therapy

UR - http://www.scopus.com/inward/record.url?scp=66349110981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349110981&partnerID=8YFLogxK

M3 - Article

C2 - 19521322

AN - SCOPUS:66349110981

VL - 7

SP - 327

EP - 334

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 5

ER -